Contineum (CTNM) announced an update on its Phase 1b positron emission tomography trial of PIPE-791, a selective antagonist of the lysophosphatidic acid 1 receptor. The company has completed enrollment of the healthy volunteer and progressive multiple sclerosis cohorts of this trial. The screening and enrollment of idiopathic pulmonary fibrosis patients to participate in this trial is ongoing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTNM:
- Positive Outlook on Contineum Therapeutics: Promising Pipeline and Strategic Collaborations Drive Buy Rating
- Contineum initiated with an Outperform at William Blair
- Promising Developments at Contineum Therapeutics Signal Undervaluation and Favorable Risk-Reward
- Contineum Therapeutics Reports Q1 2025 Financial Results
- Contineum Therapeutics Files $300M Shelf Registration